SVN-015
About SVN-015
A novel selective serotonin and dopamine re-uptake inhibitor for Stimulant (cocaine and methamphetamine) Use Disorder.
Al-Discovered Candidate for SUDs
Accepted into NIDA's Addiction Treatment Discovery Program (ATDP).
NIDA to fund and conduct preclinical safety and efficacy studies.
Strategic significance
Expands pipeline beyond AUD/PTSD into stimulant addictions - major unmet need with no approved drug treatments.
Creates a clear, non-dilutive pathway: fully funded preclinical evaluation → potential NIH clinical development grants (up to US$3m/year for 5 years).
Market opportunity
~3.0-3.2 million patients with SUDs across US, EU5, and Japan.
No approved pharmacological treatments; psychosocial interventions only, with limited outcomes.